Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Diabetic ketoacidosis with SGLT2 inhibitors.

× No keyword cloud information.

12 in total

Review 1. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.

Authors: Elisa Marilly; Judith Cottin; Natalia Cabrera; Catherine Cornu; Remy Boussageon; Philippe Moulin; Jean-Christophe Lega; François Gueyffier; Michel Cucherat; Guillaume Grenet
Journal: Diabetologia Date: 2022-08-04 Impact factor: 10.460

Review 2. Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.

Authors: Tian Gan; Yi Song; Feng Guo; Guijun Qin
Journal: Mol Biol Rep Date: 2022-08-24 Impact factor: 2.742

3. Strawberry pink blood: hypertriglyceridaemia and diabetic ketoacidosis secondary to poorly controlled type 2 diabetes mellitus.

Authors: Timothy Xin Zhong Tan; Steven Hoon Chin Lim; Joan Khoo
Journal: BMJ Case Rep Date: 2021-08-20

4. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.

Authors: Shunsaku Goto; Jun-Ya Ishikawa; Masafumi Idei; Masahiro Iwabuchi; Motoki Namekawa; Takeshi Nomura
Journal: Am J Case Rep Date: 2021-03-16

5. SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure.

Authors: Kieran F Docherty; John J V McMurray
Journal: Eur J Heart Fail Date: 2020-12-29 Impact factor: 15.534

6. ARCADIA study protocol: a phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with diabetes hospitalised with suspected or confirmed COVID-19.

Authors: Kieran McCafferty; Zoe Hollowood; Michelle Allen; Donna Lockhart; Jamie Chorlton; John Martin
Journal: BMJ Open Date: 2021-12-01 Impact factor: 2.692

Review 7. Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations.

Authors: Thiago Bosco Mendes; Alexandre Barbosa Câmara-de-Souza; Bruno Halpern
Journal: Diabetol Metab Syndr Date: 2022-03-04 Impact factor: 3.320

8. Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Who Underwent Surgery for Pancreatic Carcinoma: A Case Report.

Authors: Xiaoqian Luo; Ran Ji; Weina Lu; Hong Zhu; Libin Li; Jun Hu
Journal: Front Surg Date: 2022-02-23

Review 9. Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.

Authors: Marc Evans; Angharad R Morgan; Stephen C Bain; Sarah Davies; Umesh Dashora; Smeeta Sinha; Samuel Seidu; Dipesh C Patel; Hannah Beba; W David Strain
Journal: Diabetes Ther Date: 2022-03-29 Impact factor: 3.595

Review 10. Connexin 43: A Target for the Treatment of Inflammation in Secondary Complications of the Kidney and Eye in Diabetes.

Authors: Chelsy L Cliff; Bethany M Williams; Christos E Chadjichristos; Ulrik Mouritzen; Paul E Squires; Claire E Hills
Journal: Int J Mol Sci Date: 2022-01-06 Impact factor: 5.923